What the study found
Patients with Crohn’s disease who kept taking advanced therapies in the two months before planned bowel surgery had fewer serious anastomotic complications, not more. After adjustment for baseline differences, anastomotic leak or organ-space surgical site infection occurred in 2.43% of patients who had received an advanced therapy within 60 days of surgery, compared with 6.46% of those who had not.
There was no significant difference between the groups in superficial surgical site infection, deep incisional infection, or wound dehiscence.
How the study was done
Researchers analysed 1,150 adults with Crohn’s disease who underwent elective colectomy or proctectomy between 2021 and 2024 at 24 centres in the American College of Surgeons NSQIP Inflammatory Bowel Disease Collaborative. Advanced therapy use within 60 days before surgery was compared with no advanced therapy use. The primary outcome was anastomotic leak and/or organ-space surgical site infection within 30 days.
Among the drug classes represented, anti-TNF agents accounted for 46%, anti-IL-23 agents 33%, and anti-integrin agents 12%. The protective signal was seen in Crohn’s disease but not when ulcerative colitis was analysed separately.
Why it challenges older advice
Surgeons have long been taught to hold biologics before an operation, on the reasoning that suppressing the immune system impairs wound healing and raises infection risk. Lead author Nicholas C. Neel, a surgery resident at the University of California San Diego, described that concern as considerably weaker than previously assumed, with the data now pointing in the opposite direction.
The authors suggest the likely explanation is not a direct drug effect but better disease control: patients whose inflammation is well suppressed come to surgery with less systemic inflammation and healthier mucosa, and tissue in that state holds a join together more reliably.
What the study cannot show
This is a retrospective cohort, so it demonstrates association rather than cause. Odds ratios and confidence intervals were not reported in the press summary, and the authors call for larger datasets with enough power to analyse each drug class separately. The findings apply only to elective surgery – urgent and emergency operations proceed regardless of medication status.
What this means for doctors and students
- For colorectal surgeons: routinely stopping advanced therapy before planned Crohn’s surgery no longer has clear support; the decision belongs in a joint discussion with gastroenterology, weighed against the risk of a flare while off treatment.
- For gastroenterologists: the finding strengthens the argument for entering surgery with disease well controlled rather than deliberately washing out therapy.
- For dentists and oral surgeons: the same reflex exists in dentistry – pausing immunomodulators before extractions or implants. This study is a reminder that the stop-the-drug instinct should rest on evidence for that specific drug and procedure, and that the medication history, including biologics, belongs in every surgical assessment.
- For students: a clear example of confounding by indication working in an unexpected direction, and of why “stop the immunosuppressant” became dogma before it was tested.
Source: American College of Surgeons / Journal of the American College of Surgeons















